

# Otonomy Inc (OTIC) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/OD4252CC9BAEN.html>

Date: November 2021

Pages: 47

Price: US\$ 125.00 (Single User License)

ID: OD4252CC9BAEN

## Abstracts

Otonomy Inc (OTIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

Otonomy Inc (Otonomy) develops and markets treatments for diseases and disorders of the ear. The company's Otiprio is US FDA approved ciprofloxacin otic suspension indicated during tympanostomy tube placement surgery in pediatric patients and otitis externa. Its pipeline portfolio encompasses Otividex for the treatment of meniere's disease; OTO-313 for the treatment of tinnitus; OTO-510 for the treatment of cisplatin-induced hearing loss; OTO-413 for the treatment of synaptopathy hearing loss; and OTO-6XX for the treatment of severe hearing loss. The company is also investigating a preclinical program on GJB2 gene therapy in collaboration with AGTC for treatment of congenital hearing loss. It employs its proprietary formulation technology that uses a thermosensitive gel and drug microparticles for enabling single dose treatment by a physician. Otonomy is headquartered in San Diego, California, the US.

### Otonomy Inc Key Recent Developments

Nov 11,2021: Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Oct 27,2021: Otonomy announces multiple presentations at Neuroscience 2021 Meeting

Aug 19,2021: Otonomy Appoints Jill Broadfoot to Board of Directors

Aug 04,2021: Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Jul 28,2021: Otonomy to Report Second Quarter 2021 Financial Results and Provide Corporate Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

Otonomy Inc - Key Facts  
Otonomy Inc - Key Employees  
Otonomy Inc - Key Employee Biographies  
Otonomy Inc - Major Products and Services  
Otonomy Inc - History  
Otonomy Inc - Company Statement  
Otonomy Inc - Locations And Subsidiaries  
Head Office

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
Otonomy Inc - Business Description  
R&D Overview  
Otonomy Inc - Corporate Strategy  
Otonomy Inc - SWOT Analysis  
SWOT Analysis - Overview  
Otonomy Inc - Strengths  
Otonomy Inc - Weaknesses  
Otonomy Inc - Opportunities  
Otonomy Inc - Threats  
Otonomy Inc - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

### **SECTION 4 – COMPANY’S LIFESCENCES FINANCIAL DEALS AND ALLIANCES**

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Otonomy Inc, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Nov 11, 2021: Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Oct 27, 2021: Otonomy announces multiple presentations at Neuroscience 2021 Meeting

Aug 19, 2021: Otonomy Appoints Jill Broadfoot to Board of Directors

Aug 04, 2021: Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Jul 28, 2021: Otonomy to Report Second Quarter 2021 Financial Results and Provide Corporate Update

May 11, 2021: Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 04, 2021: Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update

Apr 06, 2021: Otonomy to Present at the Needham Virtual Healthcare Conference

Feb 25, 2021: Otonomy to Participate in Three Upcoming Investor Conferences

Feb 17, 2021: Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting

## **SECTION 6 – APPENDIX**

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Otonomy Inc, Key Facts  
Otonomy Inc, Key Employees  
Otonomy Inc, Key Employee Biographies  
Otonomy Inc, Major Products and Services  
Otonomy Inc, History  
Otonomy Inc, Key Competitors  
Otonomy Inc, Ratios based on current share price  
Otonomy Inc, Annual Ratios  
Otonomy Inc, Annual Ratios (Cont...1)  
Otonomy Inc, Annual Ratios (Cont...2)  
Otonomy Inc, Interim Ratios  
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Otonomy Inc, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## List Of Figures

### LIST OF FIGURES

Otonomy Inc, Performance Chart (2016 - 2020)

Otonomy Inc, Ratio Charts

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Otonomy Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



## I would like to order

Product name: Otonomy Inc (OTIC) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/OD4252CC9BAEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OD4252CC9BAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970